Immune Pharmaceuticals Licenses a Novel Bispecific Antibody Technology

News   Dec 29, 2015

 
Immune Pharmaceuticals Licenses a Novel Bispecific Antibody Technology
 
 
 

RELATED ARTICLES

Deficiency of Innate Immune Adaptor TRIF Linked to Neurodegeneration

News

Research has revealed that deficiency of the innate immune adaptor TRIF, which is essential for certain Toll-like receptor signaling cascades, significantly shortened survival time of ALS mice.

READ MORE

PhoreMost and Plexxikon Collaborate to Identify Novel Drug Targets

News

PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.

READ MORE

‘Bad’ Antibodies Provide Crucial Protection Against Invading Microbes

News

In a world first, scientists have revealed how a population of 'bad' antibodies in the immune system - which are usually 'silenced' because they can harm the body - can provide crucial protection against invading microbes.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE